A Genotype-Guided Strategy for Oral P2Y(12) Inhibitors in Primary PCI

Autor: Claassens, Daniel M F, Vos, Gerrit J A, Bergmeijer, Thomas O, Hermanides, Renicus S, van 't Hof, Arnoud W J, van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul R, Dewilde, Willem J M, Janssen, Paul W A, Kelder, Johannes C, Postma, Maarten J, de Boer, Anthonius, Boersma, Cornelis, Deneer, Vera H M, Ten Berg, Jurriën M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology

Publikováno v: New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOCIETY
New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 381, 1621. Massachussetts Medical Society
New England Journal of Medicine, 381(17), 1621. Massachussetts Medical Society

BackgroundIt is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y(12) inhibitors.MethodsWe conducted a randomized, open-label, assessor-blinded trial in which patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733c98faebcd29c4b96c53bc67fcb7de
https://hdl.handle.net/11370/650391a9-784b-433f-a595-a7bf8062502a

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Autor: Gimbel, Marieke, Qaderdan, Khalid, Willemsen, Laura, Hermanides, Rik, Bergmeijer, Thomas, de Vrey, Evelyn, Heestermans, Ton, Tjon Joe Gin, Melvyn, Waalewijn, Reinier, Hofma, Sjoerd, den Hartog, Frank, Jukema, Wouter, von Birgelen, Clemens, Voskuil, Michiel, Kelder, Johannes, Deneer, Vera, Ten Berg, Jurriën, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: The Lancet HIV, 395(10233), 1374. Lancet Publishing Group
Lancet, 395(10233), 1374-1381. ELSEVIER SCIENCE INC

Summary Background Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome. However, data about optimal platelet inhibition in older patients are scarce. We aimed to investigat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e838210c3b46b770b6716f833278a5
https://dspace.library.uu.nl/handle/1874/408889

A multinational trial of prasugrel for sickle cell vaso-occlusive events

Autor: David C. Rees, Raffaella Colombatti, Miguel R. Abboud, Nancy Robitaille, Hoda Hassab, Catherine I. Segbefia, Chunmei Zhou, Julie Kanter, Tsiri Agbenyega, Patricia B. Brown, Dmitry Zamoryakhin, Videlis Nduba, Janet Oyieko, Bernhards Ogutu, Lori E. Heath, Joseph A. Jakubowski, Matthew M. Heeney, Baba Inusa, Carolyn Hoppe

Publikováno v: Heeney, M M, Hoppe, C C, Abboud, M R, Inusa, B, Kanter, J, Ogutu, B, Brown, P B, Heath, L E, Jakubowski, J A, Zhou, C, Zamoryakhin, D, Agbenyega, T, Colombatti, R, Hassab, H M, Nduba, V N, Oyieko, J N, Robitaille, N & Segbefia, C I & Rees, D C 2016, ' A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events ', New England Journal of Medicine, vol. 374, no. 7, pp. 625-635 . https://doi.org/10.1056/NEJMoa1512021

BACKGROUNDSickle cell anemia is an inherited blood disorder that is characterized by painfulvaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84bbb6aa9c565795e55cf15d73bc3734
http://hdl.handle.net/11577/3353240